

UNIVERSITY OF MINNESOTA

Twin Cities Campus

Research Subjects' Protection Programs

*Institutional Review Board: Human Subjects Committee (IRB)
Institutional Animal Care and Use Committee (IACUC)*

*Mayo Mail Code 820
D-528 Mayo Memorial Building
420 Delaware Street S.E.
Minneapolis, MN 55455*

November 07, 2002

Harvey L. Sharp
Pediatrics
Box 185 Mayo
Minneapolis Campus

*612-626-5654
Fax: 612-626-6061
irb@umn.edu
iacuc@umn.edu
<http://www.research.umn.edu/subjects/>*

Re: "Liver Tissue Procurement and Distribution System for Tissue from Patients with Liver Tumor"

Human Subjects Code Number: 9812M00046

Dear Dr. Sharp:

Please note this letter replaces our letter to you dated November 5, 2002.

The IRB: Human Subjects Committee received your response to its stipulations for renewal. Since this information satisfies the conditions set by the IRB, approval for the recent renewal is confirmed in our files.

The consent form received October 8, 2002 is also approved.


For your records and for grant certification purposes, the approval date for the referenced project is July 31, 2002 and the Assurance of Compliance number is FWA00000312 (Fairview Health Systems Research FWA00000325). Approval for the project will expire one year from that date. You will receive a report form two months before the expiration date.

As Principal Investigator of this project, you are required by federal regulations to inform the IRB of any proposed changes in your research that will affect human subjects. Changes should not be initiated until written IRB approval is received. Adverse events should be reported to the IRB as they occur. Research projects are subject to continuing review.

If you have any questions, please call the IRB office at (612)-626-5654.

The IRB wishes you continued success with your research.

Sincerely,


Carol Siegel, MLS, CB
Assistant Director

CS/gc

CC: Rashmi Kaul, Timothy Sielaff, James Wang

Memo

To: Rashmi Kaul, Ph. D.
Biochemistry & Microbiology

From: Stephen Eddy, D.O. *SE 3/3/04*
Chairman, Institutional Review Board

Date: March 3, 2004

Re: Protocol - IRB #2003012
Exempt Approval/Begin Study

Title: Role of Hormones and Complement Regulatory Proteins in Hepatitis C
and Hepatocellular carcinoma.

Thank you for confirming the tissue you will be working with is de-identified.
Thank you also for reminding us that exempt research does not get a continuing review, therefore, there is no updated letters from the Universities of Minnesota and Pittsburgh.

You are free to begin your study. Any revisions or amendments to the approved protocol must be submitted to the OSU-CHS Institutional Review Board and approved before implementation.

If you have any questions please contact: Teri Bycroft, IRB Administrator at (918) 699-8643.